01887nas a2200265   4500000000100000000000100001008004100002260000900043653002600052653002100078653002400099653003100123653001600154653002800170653001400198653001900212653002800231100002200259245009300281856006700374300001200441490000600453520114800459022001401607       2023                            d  c202310acontext of use assays10aDrug development10ahuman model systems10amicrophysiological systems10amodel-omics10anew alternative methods10aorganoids10aorgans-on-chip10aPharmaceutical industry1 aKimberly A. Homan00aIndustry Adoption of Organoids and Organs-on-Chip Technology: Toward a Paradox of Choice  uhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adbi.202200334  a22003340 v73 aDuring the last decade, organoid and organs-on-chip technologies have significantly enhanced the ability to model human biology in vitro. For the pharmaceutical industry, this represents an opportunity to augment, or possibly replace, traditional preclinical animal studies with more clinically predictive tools. In the last few years, the marketplace for new human model systems has expanded rapidly. While pharma companies welcome the breadth of new options, ample choice can be paralyzing. Even for experts from the model developer community who are now filling the ranks in the industry, the pairing of the right model for a specific, fit-for-purpose biological question can be daunting. As a community, the adoption of these models can be hastened in the industry by publishing high dimensional datasets (e.g., multiomic, imaging, functional, etc.) on existing model systems, termed model-omics, and storing them in publicly accessible databases. This action will allow for quick cross-model comparisons and provide a sought-after rationale for either routine or fit-for-purpose use of organoids or organs-on-chip during drug development.  a2701-0198